Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma
Batool Shannan(Vrije Universiteit Brussel), Alexander Roesch(University of Regensburg), Jochen Utikal(University of Mannheim), Thomas G. P. Grünewald(German Cancer Research Center), Ralf Gutzmer(Medizinische Hochschule Hannover), Renáta Váraljai(Vrije Universiteit Brussel), Verena Jendrossek(University of Duisburg-Essen), Susanne Horn(Vrije Universiteit Brussel), Felix C. E. Vogel(German Cancer Research Center), Andrea Forschner(University Children's Hospital Tübingen), David Rafei‐Shamsabadi(University of Freiburg), Giuseppina Sannino(Ludwig-Maximilians-Universität München), Dirk Schadendorf(University of Mannheim), Friedegund Meier(University of Tübingen), Joachim Klode(University of Duisburg-Essen), Ricarda Rauschenberg(National Center for Tumor Diseases), Lucie Heinzerling(University of St.Gallen), Johann Matschke(University of Duisburg-Essen), Johannes Bruns(National Center for Tumor Diseases), Elisabeth Livingstone(University of Duisburg-Essen), Dana Westphal(German Cancer Research Center), Björn Scheffler(German Cancer Research Center), Carola Berking(Ludwig-Maximilians-Universität München), Lisa Zimmer(The University of Sydney), A. Hoewner(University of Duisburg-Essen), Evelyn Dabrowski(Klinikum Ludwigshafen), Martin Stuschke(Essen University Hospital), Aruna Marchetto(Ludwig-Maximilians-Universität München), Diana Klein(University of Duisburg-Essen), Heike Chauvistré(Vrije Universiteit Brussel), Patrick Terheyden(Saint John's Health Center)
Cited by 26
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k